Research programme: respiratory syncytial virus fusion inhibitors - Panacos PharmaceuticalsAlternative Names: RSV fusion inhibitors - Panacos Pharmaceuticals
Latest Information Update: 15 Apr 2008
At a glance
- Originator Panacos Pharmaceuticals Inc
- Class Small molecules
- Mechanism of Action Viral fusion protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 15 Mar 2005 Panacos Pharmaceuticals has been acquired and merged into V.I. Technologies
- 30 Aug 2002 Preclinical trials in Respiratory syncytial virus infections in USA (unspecified route)